iBio rises 16% as it says COVID vaccine candidate may be effective against Omicron

Nov. 29, 2021 10:38 AM ETiBio, Inc. (IBIO)By: Jonathan Block, SA News Editor1 Comment

new south african Omicron covid variant

franckreporter/iStock via Getty Images

  • iBio (IBIO +14.7%) says that its next-generation COVID-19 vaccine candidate, IBIO-202, may be effective against the Omicron variant.
  • "Omicron’s mutations do not occur in the region selected for our IBIO-202 [nucleocapsid] protein subunit vaccine candidate, as was the case

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.